share_log

TransMedics | 8-K: TransMedics Reports Second Quarter 2024 Financial Results

TransMedics | 8-K: TransMedics Reports Second Quarter 2024 Financial Results

TransMedics | 8-K:TransMedics公布2024年第二季度财务业绩
美股SEC公告 ·  2024/08/01 05:12

Moomoo AI 已提取核心信息

TransMedics Group, Inc. reported strong financial results for Q2 2024, with total revenue of $114.3 million, a 118% increase YoY. The company generated net income of $12.2 million or $0.35 per diluted share, compared to a net loss in Q2 2023. Growth was driven by increased utilization of the Organ Care System (OCS) and the launch of TransMedics logistics services.Gross margin was 61%, down from 70% in Q2 2023 due to a higher proportion of service revenue. Operating expenses increased to $56.8 million, reflecting investments in R&D and organizational growth. Cash position remained strong at $362.8 million as of June 30, 2024.Based on these results, TransMedics raised its full-year 2024 revenue guidance to $425-$445 million, representing 76-84% growth YoY. The company also highlighted recent achievements, including the expansion of its aircraft fleet and the publication of its 2023 ESG update report.
TransMedics Group, Inc. reported strong financial results for Q2 2024, with total revenue of $114.3 million, a 118% increase YoY. The company generated net income of $12.2 million or $0.35 per diluted share, compared to a net loss in Q2 2023. Growth was driven by increased utilization of the Organ Care System (OCS) and the launch of TransMedics logistics services.Gross margin was 61%, down from 70% in Q2 2023 due to a higher proportion of service revenue. Operating expenses increased to $56.8 million, reflecting investments in R&D and organizational growth. Cash position remained strong at $362.8 million as of June 30, 2024.Based on these results, TransMedics raised its full-year 2024 revenue guidance to $425-$445 million, representing 76-84% growth YoY. The company also highlighted recent achievements, including the expansion of its aircraft fleet and the publication of its 2023 ESG update report.
TransMedics集团公司公布了2024年第二季度强劲的财务业绩,总营业收入为11430万,较去年同期增长118%。公司实现净利润1220万,即每股稀释后收益0.35美元,而2023年第二季度则出现净亏损。增长的驱动因素是对器官护理系统(OCS)的利用率提高以及TransMedics物流服务的推出。毛利率为61%,低于2023年第二季度的70%,这是由于服务收入比例较高。营业费用增加至5680万,反映了在研发和组织增长方面的投资。截至2024年6月30日,现金状况依然强劲,达到36280万。根据这些结果,TransMedics将2024年全年的营业收入指引提高至425-$44500万,代表76%-84%的同比增长。公司还强调了近期的成就,包括其飞机机队的扩展和2023年ESG更新报告的发布。
TransMedics集团公司公布了2024年第二季度强劲的财务业绩,总营业收入为11430万,较去年同期增长118%。公司实现净利润1220万,即每股稀释后收益0.35美元,而2023年第二季度则出现净亏损。增长的驱动因素是对器官护理系统(OCS)的利用率提高以及TransMedics物流服务的推出。毛利率为61%,低于2023年第二季度的70%,这是由于服务收入比例较高。营业费用增加至5680万,反映了在研发和组织增长方面的投资。截至2024年6月30日,现金状况依然强劲,达到36280万。根据这些结果,TransMedics将2024年全年的营业收入指引提高至425-$44500万,代表76%-84%的同比增长。公司还强调了近期的成就,包括其飞机机队的扩展和2023年ESG更新报告的发布。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息